Andreatta KN - Search Results

1

Drug Susceptibility and Viral Fitness of HIV-1 with Integrase Strand Transfer Inhibitor Resistance Substitution Q148R or N155H in Combination with Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Resistance Substitutions.

Andreatta KN, Miller MD, White KL. Andreatta KN, et al. Antimicrob Agents Chemother. 2015 Nov 16;60(2):757-65. doi: 10.1128/AAC.02096-15. Print 2016 Feb. Antimicrob Agents Chemother. 2015. PMID: 26574015 Free PMC article.

2

HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro.

Andreatta K, Miller MD, White KL. Andreatta K, et al. J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):367-74. doi: 10.1097/QAI.0b013e31827b55f1. J Acquir Immune Defic Syndr. 2013. PMID: 23187937

3

Baseline antiretroviral resistance mutations and treatment-emergent resistance in HIV-1 RNA-suppressed patients switching to EVG/COBI/FTC/TDF or continuing on their PI-, NNRTI-, or RAL-based regimen.

Andreatta K, Kulkarni R, Abram ME, Nguyen T, Cao H, Miller MD, White KL. Andreatta K, et al. J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):519-26. doi: 10.1097/QAI.0000000000000503. J Acquir Immune Defic Syndr. 2015. PMID: 25559592

4

Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.

Porter DP, Toma J, Tan Y, Solberg O, Cai S, Kulkarni R, Andreatta K, Lie Y, Chuck SK, Palella F, Miller MD, White KL. Porter DP, et al. HIV Clin Trials. 2016 Feb;17(1):29-37. doi: 10.1080/15284336.2015.1115585. HIV Clin Trials. 2016. PMID: 26899540 Clinical Trial.

5

Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.

Andreatta K, Willkom M, Martin R, Chang S, Wei L, Liu H, Liu YP, Graham H, Quirk E, Martin H, White KL. Andreatta K, et al. J Antimicrob Chemother. 2019 Dec 1;74(12):3555-3564. doi: 10.1093/jac/dkz347. J Antimicrob Chemother. 2019. PMID: 31430369 Free PMC article. Clinical Trial.

6

Brief Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials.

D'Antoni ML, Andreatta K, Acosta R, Martin H, Chang S, Martin R, White KL. D'Antoni ML, et al. J Acquir Immune Defic Syndr. 2022 Apr 1;89(4):433-440. doi: 10.1097/QAI.0000000000002888. J Acquir Immune Defic Syndr. 2022. PMID: 34897227 Free PMC article. Clinical Trial.

7

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.

Margot NA, Hluhanich RM, Jones GS, Andreatta KN, Tsiang M, McColl DJ, White KL, Miller MD. Margot NA, et al. Among authors: andreatta kn. Antiviral Res. 2012 Feb;93(2):288-296. doi: 10.1016/j.antiviral.2011.12.008. Epub 2011 Dec 16. Antiviral Res. 2012. PMID: 22197635

8

Impact of primary elvitegravir resistance-associated mutations in HIV-1 integrase on drug susceptibility and viral replication fitness.

Abram ME, Hluhanich RM, Goodman DD, Andreatta KN, Margot NA, Ye L, Niedziela-Majka A, Barnes TL, Novikov N, Chen X, Svarovskaia ES, McColl DJ, White KL, Miller MD. Abram ME, et al. Among authors: andreatta kn. Antimicrob Agents Chemother. 2013 Jun;57(6):2654-63. doi: 10.1128/AAC.02568-12. Epub 2013 Mar 25. Antimicrob Agents Chemother. 2013. PMID: 23529738 Free PMC article.

9

Reduced viral fitness and lack of cross-class resistance with integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations.

Andreatta KN, Goodman DD, Miller MD, White KL. Andreatta KN, et al. Antimicrob Agents Chemother. 2015;59(6):3441-9. doi: 10.1128/AAC.00040-15. Epub 2015 Mar 30. Antimicrob Agents Chemother. 2015. PMID: 25824231 Free PMC article.

10

HIV-1 Proviral Sequence and Treatment Outcome of Virologically Suppressed Patients Switching to Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate.

Andreatta K, Chang S, Martin R, Acosta R, Daeumer M, Thielen A, Miller MD, White KL. Andreatta K, et al. J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):e45-e51. doi: 10.1097/QAI.0000000000001757. J Acquir Immune Defic Syndr. 2018. PMID: 29781878 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

19 results

Search Page

Filters